| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/23/2002 | WO2002040541A2 Transporters and ion channels |
| 05/23/2002 | WO2002040540A2 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | WO2002040505A2 Dibenzoxazepine alpha v integrin receptor antagonist |
| 05/23/2002 | WO2002040484A2 Novel imidazole derivatives, production method thereof and use thereof |
| 05/23/2002 | WO2002040448A1 Pyridone derivatives as ap2 inhibitors |
| 05/23/2002 | WO2002040446A1 Glucagon antagonist/inverse agonist |
| 05/23/2002 | WO2002040445A1 Glucagon antagonists/inverse agonists |
| 05/23/2002 | WO2002040070A2 Method for restoring a damaged or degenerated intervertebral disc |
| 05/23/2002 | WO2002040058A2 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
| 05/23/2002 | WO2002040052A1 Inhalation of nitric oxide |
| 05/23/2002 | WO2002040034A1 Complexes of phosphate derivatives |
| 05/23/2002 | WO2002040030A1 Combination therapy for lowering and controlling intraocular pressure |
| 05/23/2002 | WO2002040027A1 Treatment of premature ejaculation |
| 05/23/2002 | WO2002040024A1 Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors |
| 05/23/2002 | WO2002040022A1 Treatment of sexual dysfunction using bombesin antagonist |
| 05/23/2002 | WO2002040021A2 Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 05/23/2002 | WO2002040016A2 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | WO2002040015A1 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease |
| 05/23/2002 | WO2002040009A1 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 05/23/2002 | WO2002040008A2 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
| 05/23/2002 | WO2002040007A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | WO2002040006A2 Treatment of anxiety disorders |
| 05/23/2002 | WO2002040004A1 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration |
| 05/23/2002 | WO2002039995A2 Combination therapy for estrogen-dependent disorders |
| 05/23/2002 | WO2002039991A2 Prevention of development of dyskinesias |
| 05/23/2002 | WO2002039990A2 Method for screening anti-proliferative compounds and inhibiting tumor growth |
| 05/23/2002 | WO2002039989A1 Novel use of combined 5-ht1a agonists and selective serotonin reuptake inhibitors |
| 05/23/2002 | WO2002039988A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | WO2002039978A1 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 05/23/2002 | WO2002039976A1 Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling |
| 05/23/2002 | WO2002039975A1 Use of at least a sulphonic amino derivative in a composition promoting skin peeling |
| 05/23/2002 | WO2002039958A2 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| 05/23/2002 | WO2002039948A2 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 05/23/2002 | WO2002039879A2 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| 05/23/2002 | WO2002034267A8 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 05/23/2002 | WO2002006213A3 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 05/23/2002 | WO2002003911B1 Prevention and treatment of alzheimer's disease |
| 05/23/2002 | WO2001097749A3 The use of synthetic, non-hormonal 21-aminosteroids and thereof |
| 05/23/2002 | WO2001096603A3 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 05/23/2002 | WO2001087284A3 Aldosterone antagonist composition for release during aldosterone acrophase |
| 05/23/2002 | WO2001081577A3 Dna encoding the prost 03 polypeptide |
| 05/23/2002 | WO2001081340A3 Heterocycles that are inhibitors of impdh enzyme |
| 05/23/2002 | WO2001079164A3 N-substituted dithiocarbamates for the treatment of biological disorders |
| 05/23/2002 | WO2001077687A3 Prion-binding peptidic ligands and methods of using same |
| 05/23/2002 | WO2001076637A3 Peptide conjugates for drug delivery |
| 05/23/2002 | WO2001074394A8 New combination of a betablocker and a cholesterol-lowering agent |
| 05/23/2002 | WO2001074348A8 Vasopeptidase inhibitors to treat isolated systolic hypertension |
| 05/23/2002 | WO2001072837A3 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 05/23/2002 | WO2001072294A3 Method of treating hepatitis delta viral infection |
| 05/23/2002 | WO2001064837A8 β NETRIN AND USES THEREOF |
| 05/23/2002 | WO2001044206A9 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 05/23/2002 | WO2001041760A9 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 05/23/2002 | WO2001040271A9 Cancer associated antigens and uses therefor |
| 05/23/2002 | WO2000071121A9 Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 05/23/2002 | US20020062488 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus |
| 05/23/2002 | US20020062044 Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules |
| 05/23/2002 | US20020061918 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 05/23/2002 | US20020061914 Benzothiazole, benzooxazole and benzoimidazole derivatives as sodium or calcium channel modulators |
| 05/23/2002 | US20020061910 Optically pure reboxetine or its methanesulfonate salt inhibits reuptake of norepinephrine |
| 05/23/2002 | US20020061908 S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methy l-1-oxo-1H,5H-benzo(i,j)quinolizine-2-carboxylic acid arginine salt microbiocides |
| 05/23/2002 | US20020061906 Aerosol compositions |
| 05/23/2002 | US20020061892 Antiviral azaindole derivatives |
| 05/23/2002 | US20020061872 For oral administration or embedded or otherwise attached to medical devices for blood collection and/or treatment |
| 05/23/2002 | US20020061866 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor |
| 05/23/2002 | US20020061860 Antisense oligonucleotide inhibition of specific histone deacetylase isoforms |
| 05/23/2002 | US20020061834 Human G-protein Chemokine receptor (CCR5) HDGNR10 |
| 05/23/2002 | US20020061569 Nuclelotide sequences for use in the prevention of proliferation of microorganisms |
| 05/23/2002 | US20020061339 Compositions and methods for use of extracts of rutaceae plants |
| 05/23/2002 | US20020061337 Administering water and/or fat-soluble cytosolic extract of pollen with Royal Jelly and Vitamin E to treat hormonal variations in fertile, peri- and post- menopausal women |
| 05/23/2002 | US20020061336 Also comprising a hydrogel, for use in the treatment of a subject by particle injection |
| 05/23/2002 | US20020061316 Immunotherapeutic stress protein-peptide complexes against cancer |
| 05/23/2002 | US20020061314 Administering to animal live vaccine containing organisms to develop immunological response, maintaining animal free from drugs effective against infectious organism for period of one life or infectious cycle of organism, administering drug |
| 05/23/2002 | US20020061304 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 05/23/2002 | US20020061303 Administering Golgi apparatus disturbing agents such as brefeldin A, nocodazole, ilimaquinone, bafilamycin, okadaic acid, retinoic acid, and mixtures |
| 05/23/2002 | US20020061300 Method and composition for treating prostate cancer |
| 05/23/2002 | US20020061294 Mononuclear phagocytes in therapeutic drug delivery |
| 05/23/2002 | US20020061292 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 05/23/2002 | US20020061289 Stem cell-based methods for preventing and treating tumor |
| 05/23/2002 | US20020061281 Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| 05/23/2002 | US20020060919 Full-wave rectifier |
| 05/23/2002 | DE10131987A1 New pyridinyl-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation |
| 05/23/2002 | DE10057754A1 New cyclic sulfonamido-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation |
| 05/23/2002 | DE10057751A1 New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation |
| 05/23/2002 | CA2763223A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | CA2460057A1 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease |
| 05/23/2002 | CA2436854A1 Pyridone derivatives as ap2 inhibitors |
| 05/23/2002 | CA2429460A1 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | CA2429455A1 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | CA2429342A1 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/23/2002 | CA2429224A1 Inhalation of nitric oxide |
| 05/23/2002 | CA2429195A1 Immunoglobulin superfamily proteins |
| 05/23/2002 | CA2429106A1 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
| 05/23/2002 | CA2429047A1 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| 05/23/2002 | CA2428850A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2002 | CA2428799A1 Combination therapy for lowering and controlling intraocular pressure |
| 05/23/2002 | CA2428754A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | CA2428753A1 Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 05/23/2002 | CA2428748A1 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 05/23/2002 | CA2428709A1 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | CA2428707A1 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration |